Coenzyme Q₁₀ alleviates tacrolimus-induced mitochondrial dysfunction in kidney

Area of Science:

• Nephrology
• Mitochondrial Biology
• Pharmacology

Background:

• Tacrolimus (Tac) is a crucial immunosuppressant, but its use is limited by significant nephrotoxicity.
• Mitochondrial dysfunction and oxidative stress are key mechanisms underlying Tac-induced kidney damage.

Purpose of the Study:

• To investigate the protective effects of coenzyme Q10 (CoQ10) against Tac-induced nephrotoxicity.
• To determine if CoQ10 can mitigate Tac-induced mitochondrial dysfunction in kidney cells and an animal model.

Main Methods:

• * In vitro: Assessed CoQ10's impact on mitochondrial reactive oxygen species (ROS) production and membrane potential in proximal tubular cells exposed to Tac.
• * In vitro: Evaluated mitochondrial respiration and ATP synthesis in the presence of Tac and CoQ10.
• * In vivo: Utilized a rat model of chronic Tac-induced nephropathy to assess CoQ10's effects on oxidative stress, kidney function, and histology.
• * Electron Microscopy: Examined mitochondrial morphology in kidney tissues.

Main Results:

• * In vitro, CoQ10 reduced Tac-induced mitochondrial ROS production and preserved mitochondrial membrane potential.
• * CoQ10 treatment improved mitochondrial function by decreasing oxygen consumption and enhancing respiration rates, indicating better ATP synthesis.
• * In vivo, CoQ10 attenuated Tac-induced oxidative stress, leading to functional and histological improvements in nephropathy.
• * Electron microscopy revealed increased mitochondrial number and volume with CoQ10 supplementation.

Conclusions:

• Coenzyme Q10 effectively improves Tac-induced mitochondrial dysfunction in kidney cells and tissues.
• CoQ10 demonstrates potential as a therapeutic strategy to reduce tacrolimus-induced nephrotoxicity.